Transcript for Johnson and Johnson set to release date for vaccine authorization
a little later. The latest on the pandemic and vaccines. So far more than 44 million Americans have received at least one dose. That's over 13% of the country. The rollout is ramping up right now. We could reach 240 million doses by the end of March once the single shot Johnson & Johnson vaccine is approved. Eva pilgrim reports from a FEMA vaccination site in Brooklyn, good morning, pimento. Eva. They're hoping to do 3,000 doses of vaccine a day here and using faith groups and buses to help people get here. This as vaccinemakers are ramping up production to get those doses out. This morning, U.S. Vaccine supplies getting a major boost, manufacturers now doubling the rate of production telling congress they're on track to deliver 600 million doses, enough to vaccinate every U.S. Adult by July. Currently on track to deliver the first 100 million doses of the vaccine by the end of March. We anticipate that that will get up to 13 million doses a week by the end of March. Reporter: Now Johnson & Johnson on the verge of becoming the third vaccine to receive emergency use authorization releasing details of its rollout saying it's ready to deliver 20 million doses of its one-dose vaccine by the end of March. Authorization could come as early as Friday. We're prepared to ship immediately upon emergency use authorization nearly 4 million doses of our vaccine. Reporter: The single dose Johnson & Johnson vaccine was found to be 85% effective in clinical trials for preventing severe illness and claims to be 100% effective at preventing deaths, even against the highly contagious south African variant. All three vaccines help the body develop immunity to the virus that causes covid-19 without having to get the illness. But there are differences. Unlike its two-dose counterparts the single-dose Johnson & Johnson vaccine doesn't need to be frozen or shipping or long-term storage. It's known as a viral vector vaccine. It uses a nonreplicating version of the harmless common cold as a vector, a carrier to deliver instructions through genetic material that prompts your body to mount immune system defenses. And this ramp-up we're seeing by vaccinemakers is what needs to happen in order for them to meet that deadline of 600 million doses by the end of July. George. Okay, Eva, thanks.
This transcript has been automatically generated and may not be 100% accurate.